Table 3 Characteristics of included trials: Trials on various other conditionsa
Trial | Clinical problem | Sample size (% dropout) | Concealment | Outcome used for meta-analysis | Intervention details | Standard basic care in all groups | |
|---|---|---|---|---|---|---|---|
Allen et al. [33] | Depression | 38 (11%) | Unclear | Hamilton Rating Scale for Depression after 8 weeks | N:12 D:n.i. T:8w | Ac:A CA S:I A 2 | Probably no treatment at all |
Allen et al. [34] | Depression | 157 (13%) | Unclear | Hamilton Rating Scale for Depression after 8 weeks (PMOM) | N:12 D:20 T:8w | Ac:A CA S:I A 2 | Probably no treatment at all |
Asher et al. [35] | Induction of labor | 89 (0) | Adequate | PMOM: Time to delivery | N:7 D:30 T:2w | Ac:C CA S:I A 1 | Routine prenatal care |
Aune et al. [36] | Recurrent urinary tract infections | 67 (unclear) | Unclear | Patients without infection | N:8 D:20 T:4w | Ac:A CA S:I C 1 | No treatment |
Avis et al. [37] | Menopausal hot flashes | 56 (0) | Adequateb | Reduction in hot flash frequencyb | N:16 D:30 T:8w | Ac:B CA S:B A 2 | Continuation of nondrug treatment used before trial |
Bullock et al. [40] | Addiction (cocaine abuse) | 236 (59%) | Unclear | Addiction severity scale drug use in week 8 | N:28 D:45 T:8w | Ac:C EarA S:I C 2 | Eden psychosocial programmingd |
Freire et al. [47] | Moderate obstructive sleep apnea syndrome | 36 (28%) | Unclear | Apnea-hypopnea index after 12 weeks | N:10 D:30 T:10w | Ac:C CA S:I C 1 | Offer to receive sleep hygiene counseling |
Lembob et al. [54] | Irritable bowel syndrome (IBS) | 231 (8%) | Adequate | PMOM: IBS Global Improvement Scale week 3 | N:6 D:20 T:3w | Ac:B CA S:II B 1 | Continuation of drugs and diet used before trial |
Medici et al. [57] | Stable chronic asthma | 66 (0) | Unclear | PMOM: Peak expiratory flow variability baseline to 4 months | N:16 D:20 T:8w | Ac:C CA S:I C 1 | Asthma drugs adapted if necessaryd |
Rampes et al. [60] | Addiction (alcohol abuse) | 59 (54%) | Adequatec | PMOM: VAS craving for alcohol after 8 weeks | N: 6 D: 30 T: 6w | Ac:C EarA S:I C 2 | Individual counseling and group therapyd |
Röschke et al. [61] | Depression | 70 (unclear) | Unclear | Responder according to Global Assessment Scale (GAS) | N: 12 D: 30 T: 4w | Ac:C CA S:I C 1 | Mianserin 90 to 120 mg/day in all groupsd |
Smith et al. [63] | Nausea and vomiting during pregnancy | 445 (25%) | Adequate | Rhodes Index of Nausea after 4 weeks | N: 5 D: 20 T: 4w | Ac:A CA S:I C 1 | Pretrial treatment continued; lifestyle recommendations |
Tremeau et al. [65] | Cervical maturation 37th to 38th pregnancy week | 98 (18%) | Unclear | PMOM: Bishop score baseline to 10 days | N: 3 D: 20 T: 1w | Ac:C CA S:I C 1 | None |
Wang et al. [66] | Low-back and pelvic pain during pregnancy | 159 (4%) | Adequatec | PMOM: VAS pain change after 1 weekc | N: 1 D:c T: 1w | Ac:C EA S:I C 2 | Acetaminophen and other self-care if needed |
Worner et al. [68] | Addiction (alcohol abuse) | 56 (95%) | Unclear | Patients with either relapse or inpatient detoxification | N: n.i. D: 30 T: 12w | Ac:C CA S:II C 1 | Counseling and group therapyd |